摘要
背景:无论是在治疗开始还是在初始阳性反应后发展,耐药性是抗肿瘤治疗的主要限制因素。在铂类药物的情况下,铜转运蛋白已被发现通过促进进口或有利于铂的输出和失活来干扰药物贩运。 方法:使用强大的光谱,光谱和计算方法,可以深入了解铂类药物与转运蛋白金属结合结构域相互作用的模式。 结果:这篇综述文章重点介绍了铂类药物可以与铜离子竞争结合转运蛋白以及随之而来的结构和生物效应的模式。详细讨论了三种类型的转运蛋白:铜转运蛋白1(Ctr1),主要负责Cu +吸收;抗氧化剂-1铜伴侣(Atox1),负责细胞质内铜的转移;和铜ATP酶(ATP7A / B),负责将铜输出到特定的亚细胞区室和细胞外。 结论:本综述总结的知识体系有助于塑造当前的化疗方案,优化铂类药物的疗效(特别是与耐药性相关),并减轻对铜代谢的不利影响。
关键词: 铂类抗癌药物,铜伴侣,铜ATP酶,耐药性,核磁共振波谱,质谱。
Current Medicinal Chemistry
Title:Monitoring Interactions Inside Cells by Advanced Spectroscopies: Overview of Copper Transporters and Cisplatin
Volume: 25 Issue: 4
关键词: 铂类抗癌药物,铜伴侣,铜ATP酶,耐药性,核磁共振波谱,质谱。
摘要: Background: Resistance, either at the onset of the treatment or developed after an initial positive response, is a major limitation of antitumor therapy. In the case of platinum- based drugs, copper transporters have been found to interfere with drug trafficking by facilitating the import or favoring the platinum export and inactivation.
Methods: The use of powerful spectroscopic, spectrometric and computational methods has allowed a deep structural insight into the mode of interaction of platinum drugs with the metal-binding domains of the transporter proteins.
Results: This review article focuses on the mode in which platinum drugs can compete with copper ion for binding to transport proteins and consequent structural and biological effects. Three types of transporters are discussed in detail: copper transporter 1 (Ctr1), the major responsible for Cu+ uptake; antioxidant-1 copper chaperone (Atox1), responsible for copper transfer within the cytoplasm; and copper ATPases (ATP7A/B), responsible for copper export into specific subcellular compartments and outside the cell.
Conclusion: The body of knowledge summarized in this review can help in shaping current chemotherapy to optimize the efficacy of platinum drugs (particularly in relation to resistance) and to mitigate adverse effects on copper metabolism.
Export Options
About this article
Cite this article as:
Monitoring Interactions Inside Cells by Advanced Spectroscopies: Overview of Copper Transporters and Cisplatin, Current Medicinal Chemistry 2018; 25 (4) . https://dx.doi.org/10.2174/0929867324666171110141311
DOI https://dx.doi.org/10.2174/0929867324666171110141311 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers
Current Pharmaceutical Biotechnology Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry Piperidin-4-one: The Potential Pharmacophore
Mini-Reviews in Medicinal Chemistry In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Strategies to Overcome Multi-Drug Resistance in Cancer Cells: the Contribution of siRNA and Nanotechnologies
Current Organic Chemistry Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience
Reviews on Recent Clinical Trials Overview of Development and Formulation of <sup>177</sup>Lu-DOTA-TATE for PRRT
Current Radiopharmaceuticals Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma
Current Cancer Drug Targets MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design Treasures Hunt in Old Mines: Terminalia chebula-Based Traditional Herbal Medicinal Products
The Natural Products Journal Therapeutic Potential of Targeting Transforming Growth Factor-beta in Colorectal Cancer: Rational and Progress
Current Pharmaceutical Design CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?
Current Gene Therapy Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets